Kategoria BISAC: Medical >> Research

This volume discusses methods used in the fields of molecular and cellular biology for detecting and studying cell death, especially in cancer and cancer therapy. Chapters in this book cover topics such as non-destructive, real-time Annexin V apoptosis assay; assessment of the immune response to tumor cell apoptosis and efferocytosis; mass cytometry assessment of cell phenotypes and signaling states in human whole blood; cell cycle analysis of ER stress and autophagy; and simultaneous detection of inflammasome activation and membrane damage during pyroptosis. Written in the highly...

Lung cancer has seen a paradigm shift in disease treatment over the past few years, with major changes in the therapeutic drugs now available as well as in the overall management approach.  For targeted and immunotherapeutic approaches, understanding the biology of acquired resistance is a key strategy that has yielded productive advances in the subsequent treatment.  Future advances also include incorporating biomarker data obtained from solid and liquid biopsies, as well as combination of immunotherapy with radiotherapy and in special populations such patients with CNS...

This volume explores the latest techniques used to study neurodevelopmental diseases (NDD) that range from molecular aspects to integrated research approaches and brain imaging in living rodents. Chapters in this book cover topics such as protocols to deliver shRNA in vitro and in vivo using lentiviral particles to knock-down specific protein expression; experimental procedures to use recombinant fluorescent probes to visualize endogenous proteins at the mammalian synapse; CRISPR/Cas9 toolkit to assess either gain- or loss-of-gene function in brain organoids; detailed protocols to use in...

This book draws a unique perspective on the regulation of access to clinical trial data as a case on research and knowledge externalities. Notwithstanding numerous potential benefits for medical research and public health, many jurisdictions have struggled to ensure access to clinical trial data, even at the level of the trial results. Pro-access policy initiatives have been strongly opposed by research-based drug companies arguing that mandatory data disclosure impedes their innovation incentives. Conventionally, access to test data has been approached from the perspective of transparency...